Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut hormone GIP may calm nausea by boosting blood flow to the abdomen

NCT ID NCT07687589

Symptom relief Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether the gut hormone GIP can reduce nausea in healthy volunteers. Nausea is triggered using other gut hormones or a medication, and GIP is given intravenously to see if it lessens the sick feeling. The goal is to better understand how the gut and brain communicate to control nausea.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Glucose-dependent Insulinotropic Polypeptide (GIP)
What this could lead to
If GIP reduces nausea, it could point toward a new treatment for nausea without strong side effects.
What could go wrong
This is a small, early study in healthy people, so results may not apply to patients with chronic nausea. The effect may be weak or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women, age of 18-60 years * BMI between 19-27 kg/m2 (both included) * informed consent Exclusion Criteria: * Current or past treatment with GLP-1 or GIP/GLP-1 receptor-targeting compounds within the last six months * Gastrointestinal disorders that the investigator evaluates could interfere with induction of nausea (e.g. gastroparesis, functional dyspepsia and GI surgery) * Neurological disorders affecting nausea (e.g. severe migraines and neuropathy) * Any known eating disorders (e.g. anorexia nervosa and bulimia) * Pregnancy or breastfeeding * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (\> 2 times normal values) or present hepatobiliary disease * Kidney disease (estimated glomerular filtration rate (eGFR)\<90 ml/min/1.73 m2) at screening * Severe arteriosclerotic heart disease or heart failure (NYHA class II-IV) * Glycated hemoglobin (HbA1c) ³ 48 mmol/mol and/or diagnosed type 1 or type 2 diabetes * Any condition that the investigator evaluates would interfere with study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Emesis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Nausea Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Emesis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Center for Clinical Metabolic Research, Herlev-Gentofte Hospital

    Hellerup, 2900, Denmark